Target intelligence / Profile preview

Histone-lysine N-methyltransferase SETD7 (SETD7)

Target
SETD7
Molecular classification
Enzyme, Histone modification, Transferase
01

Overview

Histone-lysine N-methyltransferase SETD7 (commonly known as SET7/9) is a member of the SET domain-containing family of methyltransferases that specifically catalyzes the monomethylation of lysine 4 on histone H3 (H3K4me1), a modification associated with active gene transcription. Beyond histones, SET7/9 is unique in its ability to methylate a wide array of non-histone proteins, including the tumor suppressor p53, estrogen receptor alpha (ER-alpha), TAF10, DNMT1, and YAP, thereby regulating diverse cellular processes such as cell cycle progression, apoptosis, and signal transduction. Due to its involvement in pathological states like cancer progression, chronic kidney disease, and diabetic complications, SET7/9 has emerged as an attractive therapeutic target. Pharmacological inhibitors, such as the highly selective chemical probe (R)-PFI-2 and the repurposed drug cyproheptadine, target the substrate-binding pocket of the enzyme to block its methyltransferase activity. However, because of its context-dependent roles as both an oncogene and a tumor suppressor, as well as its broad physiological functions, therapeutic targeting of SET7/9 presents significant challenges regarding selectivity and safety.

Other names
SET7/9SET7SET9KMT7KIAA1717Lysine N-methyltransferase 7SET domain-containing protein 7Histone H3-K4 methyltransferase SETD7
02

Mechanism of action

Inhibition of histone-lysine N-methyltransferase activity, typically through substrate-competitive or cofactor-dependent mechanisms, preventing the monomethylation of histone H3 lysine 4 (H3K4me1) and non-histone substrates.

03

Biological functions

Histone methylationChromatin remodelingTranscription regulationProtein methylationCell cycle regulationApoptosisCell proliferationSignal transduction
04

Disease associations

CancerInflammationDiabetic kidney diseaseRenal fibrosisDiabetesCardiovascular diseaseNeurodegenerative disease
05

Safety considerations

Off-target effects due to broad non-histone substrate methylationPotential to aggravate diabetic retinopathy due to neoangiogenesisContext-dependent role in tumorigenesis (acting as both oncogene and tumor suppressor)Disruption of normal physiological processes like pancreatic beta-cell function and muscle regeneration
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

H3K4me1 (Histone H3 lysine 4 monomethylation)SETD7 expression levelYAP1 nuclear localizationSEMA3G expression

Beyond the preview

Go deeper on Histone-lysine N-methyltransferase SETD7 (SETD7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone-lysine N-methyltransferase SETD7 (SETD7).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call